OBJECTIVES: Alaska Native (AN) people have a high prevalence of tobacco use and associated morbidity and mortality when compared with the general USA population. Variations in the CYP2A6 and CYP2B6 genes, encoding enzymes responsible for nicotine metabolic inactivation and procarcinogen activation, have not been characterized in AN and may contribute toward the increased risk. METHODS: AN people (n=400) residing in the Bristol Bay region of South Western Alaska were recruited for a cross-sectional study on tobacco use. They were genotyped for CYP2A6*1X2A, *1X2B, *1B, *2, *4, *7, *8, *9, *10, *12, *17, *35 and CYP2B6*4, *6, *9 and provided plasma and urine samples for the measurement of nicotine and metabolites. RESULTS: CYP2A6 and CYP2B6 variant frequencies among the AN Yupik people (n=361) were significantly different from those in other ethnicities. Nicotine metabolism [as measured by the plasma and urinary ratio of metabolites trans-3'-hydroxycotinine to cotinine (3HC/COT)] was significantly associated with CYP2A6 (P<0.001), but not CYP2B6 genotype (P=0.95) when controlling for known covariates. It was noteworthy that the plasma 3HC/COT ratios were high in the entire Yupik people, and among the Yupik CYP2A6 wild-type participants, they were substantially higher than those in previously characterized racial/ethnic groups (P<0.001 vs. Caucasians and African Americans). CONCLUSION: Yupik AN people have a unique CYP2A6 genetic profile that associated strongly with in-vivo nicotine metabolism. More rapid CYP2A6-mediated nicotine and nitrosamine metabolism in the Yupik people may modulate the risk of tobacco-related diseases.
OBJECTIVES: Alaska Native (AN) people have a high prevalence of tobacco use and associated morbidity and mortality when compared with the general USA population. Variations in the CYP2A6 and CYP2B6 genes, encoding enzymes responsible for nicotine metabolic inactivation and procarcinogen activation, have not been characterized in AN and may contribute toward the increased risk. METHODS: AN people (n=400) residing in the Bristol Bay region of South Western Alaska were recruited for a cross-sectional study on tobacco use. They were genotyped for CYP2A6*1X2A, *1X2B, *1B, *2, *4, *7, *8, *9, *10, *12, *17, *35 and CYP2B6*4, *6, *9 and provided plasma and urine samples for the measurement of nicotine and metabolites. RESULTS:CYP2A6 and CYP2B6 variant frequencies among the AN Yupik people (n=361) were significantly different from those in other ethnicities. Nicotine metabolism [as measured by the plasma and urinary ratio of metabolites trans-3'-hydroxycotinine to cotinine (3HC/COT)] was significantly associated with CYP2A6 (P<0.001), but not CYP2B6 genotype (P=0.95) when controlling for known covariates. It was noteworthy that the plasma 3HC/COT ratios were high in the entire Yupik people, and among the Yupik CYP2A6 wild-type participants, they were substantially higher than those in previously characterized racial/ethnic groups (P<0.001 vs. Caucasians and African Americans). CONCLUSION: Yupik AN people have a unique CYP2A6 genetic profile that associated strongly with in-vivo nicotine metabolism. More rapid CYP2A6-mediated nicotine and nitrosamine metabolism in the Yupik people may modulate the risk of tobacco-related diseases.
Authors: C Lerman; C Jepson; E P Wileyto; F Patterson; R Schnoll; M Mroziewicz; N Benowitz; R F Tyndale Journal: Clin Pharmacol Ther Date: 2010-03-24 Impact factor: 6.875
Authors: Cristina Rodriguez-Antona; Alvin Gomez; Maria Karlgren; Sarah C Sim; Magnus Ingelman-Sundberg Journal: Hum Genet Date: 2009-10-08 Impact factor: 4.132
Authors: Jill C Mwenifumbo; Qian Zhou; Neal L Benowitz; Edward M Sellers; Rachel F Tyndale Journal: Pharmacogenomics Date: 2010-02 Impact factor: 2.533
Authors: Marc E Mooney; Zhong-Ze Li; Sharon E Murphy; Paul R Pentel; Chap Le; Dorothy K Hatsukami Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-06 Impact factor: 4.254
Authors: Kiersten S Derby; Kristine Cuthrell; Christian Caberto; Steven G Carmella; Adrian A Franke; Stephen S Hecht; Sharon E Murphy; Loïc Le Marchand Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-11-24 Impact factor: 4.254
Authors: Robert A Schnoll; Tony P George; Larry Hawk; Paul Cinciripini; Paul Wileyto; Rachel F Tyndale Journal: Psychopharmacology (Berl) Date: 2014-01-09 Impact factor: 4.530
Authors: Jian-Min Yuan; Heather H Nelson; Steven G Carmella; Renwei Wang; Jacquelyn Kuriger-Laber; Aizhen Jin; Jennifer Adams-Haduch; Stephen S Hecht; Woon-Puay Koh; Sharon E Murphy Journal: Carcinogenesis Date: 2017-04-01 Impact factor: 4.944
Authors: Jon O Ebbert; Herbert H Severson; Brian G Danaher; Neal L Benowitz; Darrell R Schroeder Journal: Nicotine Tob Res Date: 2015-05-14 Impact factor: 4.244
Authors: Andy Z X Zhu; Matthew J Binnington; Caroline C Renner; Anne P Lanier; Dorothy K Hatsukami; Irina Stepanov; Clifford H Watson; Connie S Sosnoff; Neal L Benowitz; Rachel F Tyndale Journal: Carcinogenesis Date: 2012-10-01 Impact factor: 4.944
Authors: Neal L Benowitz; Andy Z X Zhu; Rachel F Tyndale; Delia Dempsey; Peyton Jacob Journal: Pharmacogenet Genomics Date: 2013-03 Impact factor: 2.089